Trumpet satinash
Trumpet satinash


Used as a source of betulinic acid, which is of interest for cancer and HIV/AIDS, but there is no evidence to support its use for any condition.

The safety of trumpet satinash when used orally is unclear.

No known major interactions.

People use this for...

The fruit of trumpet satinash is sometimes consumed as food.

Pregnancy And Lactation: Insufficient reliable information available; avoid using.

There is insufficient reliable information available about the effectiveness of trumpet satinash.

Natural Medicines rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

Dosing & administration

    Adverse effects

    General: Orally, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.


    There is insufficient reliable information available about the toxicology of trumpet satinash.

    Interactions with pharmaceuticals

    None known.

    Interactions with herbs & supplements

    None known.

    Interactions with foods

    None known.

    Interactions with lab tests

    None known.

    Interactions with diseases

    None known.

    Mechanism of action

    General: The applicable part of trumpet satinash is the leaf. The leaf is of interest because it is a source of betulinic acid (29110). Other constituents of the leaf include oleanolic acid (71657) and platonic acid (29110).

    Anticancer effects: Trumpet satinash contains the constituent betulinic acid. Betulinic acid, isolated from other plants such as white birch, has been shown to have anti-cancer effects in vitro. Betulinic acid induces apoptosis of numerous cancer cell lines by inhibiting or inducing certain cellular pathways (28768,28777,28780,28783,28784,28785,28787,28788,28789,28791)(28795,28796,28797,29109). There is no evidence that trumpet satinash itself has anti-cancer effects.

    Antiparasitic effects: Trumpet satinash contains the constituent betulinic acid. Betulinic acid, isolated from other plants such as Uapaca species, has been shown to have antiparasitic effects in vitro against Plasmodium and Trypanosoma parasites (28773,28774,28775,29106). There is no evidence that trumpet satinash itself has antiparasitic effects.

    Antiviral effects: Trumpet satinash contains the constituents betulinic acid, oleanolic acid, and platonic acid (29110,71657). When isolated from trumpet satinash leaves, these constituents inhibit HIV-1 replication in vitro (29110,71657). There is no evidence that trumpet satinash itself has antiviral effects.


    There is insufficient reliable information available about the pharmacokinetics of trumpet satinash.


    28768Tan, Y., Yu, R., and Pezzuto, J. M. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 2003;9(7):2866-2875. View abstract.
    28773de Sa, M. S., Costa, J. F., Krettli, A. U., Zalis, M. G., Maia, G. L., Sette, I. M., Camara, Cde A., Filho, J. M., Giulietti-Harley, A. M., Ribeiro Dos, Santos R., and Soares, M. B. Antimalarial activity of betulinic acid and derivatives in vitro against Plasmodium falciparum and in vivo in P. berghei-infected mice. Parasitol Res 2009;105(1):275-279. View abstract.
    28774Steele, J. C., Warhurst, D. C., Kirby, G. C., and Simmonds, M. S. In vitro and in vivo evaluation of betulinic acid as an antimalarial. Phytother Res 1999;13(2):115-119. View abstract.
    28775Bringmann, G., Saeb, W., Assi, L. A., Francois, G., Sankara Narayanan, A. S., Peters, K., and Peters, E. M. Betulinic acid: isolation from Triphyophyllum peltatum and Ancistrocladus heyneanus, antimalarial activity, and crystal structure of the benzyl ester. Planta Med 1997;63(3):255-257. View abstract.
    28777Rzeski, W., Stepulak, A., Szymanski, M., Sifringer, M., Kaczor, J., Wejksza, K., Zdzisinska, B., and Kandefer-Szerszen, M. Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells. Naunyn Schmiedebergs Arch Pharmacol 2006;374(1):11-20. View abstract.
    28780Fulda, S. and Debatin, K. M. Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia 2005;7(2):162-170. View abstract.
    28783Poon, K. H., Zhang, J., Wang, C., Tse, A. K., Wan, C. K., and Fong, W. F. Betulinic acid enhances 1alpha,25-dihydroxyvitamin D3-induced differentiation in human HL-60 promyelocytic leukemia cells. Anticancer Drugs 2004;15(6):619-624. View abstract.
    28784Basu, S., Ma, R., Boyle, P. J., Mikulla, B., Bradley, M., Smith, B., Basu, M., and Banerjee, S. Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis -platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside. Glycoconj J 2004;20(9):563-577. View abstract.
    28785Fulda, S. and Debatin, K. M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med Pediatr Oncol 2000;35(6):616-618. View abstract.
    28787Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nunez, G., Krammer, P. H., Peter, M. E., and Debatin, K. M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997;57(21):4956-4964. View abstract.
    28788Fulda, S., Jeremias, I., and Debatin, K. M. Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. Oncogene 2004;23(46):7611-7620. View abstract.
    28789Rieber, M. and Rieber, M. S. Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status. Int J Cancer 2006;118(5):1135-1143. View abstract.
    28791Chen, Z., Wu, Q., Chen, Y., and He, J. Effects of betulinic acid on proliferation and apoptosis in Jurkat cells and its in vitro mechanism. J Huazhong Univ Sci Technolog Med Sci 2008;28(6):634-638. View abstract.
    28795Rabi, T., Shukla, S., and Gupta, S. Betulinic acid suppresses constitutive and TNFalpha-induced NF-kappaB activation and induces apoptosis in human prostate carcinoma PC-3 cells. Mol Carcinog 2008;47(12):964-973. View abstract.
    28796Kasperczyk, H., La Ferla-Bruhl, K., Westhoff, M. A., Behrend, L., Zwacka, R. M., Debatin, K. M., and Fulda, S. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 2005;24(46):6945-6956. View abstract.
    28797Ganguly, A., Das, B., Roy, A., Sen, N., Dasgupta, S. B., Mukhopadhayay, S., and Majumder, H. K. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death. Cancer Res 2007;67(24):11848-11858. View abstract.
    29106Nyasse, B., Nono, J. J., Nganso, Y., Ngantchou, I., and Schneider, B. Uapaca genus (Euphorbiaceae), a good source of betulinic acid. Fitoterapia 2009;80(1):32-34. View abstract.
    29109Melzig, M. F. and Bormann, H. Betulinic acid inhibits aminopeptidase N activity. Planta Med 1998;64(7):655-657. View abstract.
    29110Fujioka, T., Kashiwada, Y., Kilkuskie, R. E., Cosentino, L. M., Ballas, L. M., Jiang, J. B., Janzen, W. P., Chen, I. S., and Lee, K. H. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J Nat Prod 1994;57(2):243-247. View abstract.
    71657 Kashiwada, Y., Wang, H. K., Nagao, T., Kitanaka, S., Yasuda, I., Fujioka, T., Yamagishi, T., Cosentino, L. M., Kozuka, M., Okabe, H., Ikeshiro, Y., Hu, C. Q., Yeh, E., and Lee, K. H. Anti-AIDS agents. 30. Anti-HIV activity of oleanolic acid, pomolic acid, and structurally related triterpenoids. J Nat Prod 1998;61(9):1090-1095. View abstract. has licensed professional monographs from TRC Healthcare. Full monographs are available to Pro practitioner accounts.
    This monograph was last reviewed on 16/12/2019 22:10:04 and last updated on 16/07/2020 03:14:44. Monographs are reviewed and/or updated multiple times per month and at least once per year.
    Natural Medicines disclaims any responsibility related to medical consequences of using any medical product. Effort is made to ensure that the information contained in this monograph is accurate at the time it was published. Consumers and medical professionals who consult this monograph are cautioned that any medical or product related decision is the sole responsibility of the consumer and/or the health care professional. A legal License Agreement sets limitations on downloading, storing, or printing content from this Database. No reproduction of this monograph or any content from this Database is permitted without written permission from the publisher. It is unlawful to download, store, or distribute content from this site.